About

Following investment from Guerbet into Nuclidium, I act as an Observer in Nuclidium's Board of Directors. Its innovative CuTrace™ platform merges copper radiometals with targeted cancer molecules, speeding up the creation of new diagnostic and therapeutic solutions. This portfolio enhances safety and efficacy, offering cost-effective solutions for hospitals and patients. Its unique diagnostic-to-therapeutic model simplifies development, tackling manufacturing and distribution challenges to increase flexibility for medical providers.

Company details may include data from People Data Labs, licensed CC BY 4.0.